The Ultimate Growth Hormone Stack: CJC-1295, Ipamorelin & MK-677

The combination of a GHRH analog and a GHRP represents the most well-characterized synergy in peptide research. CJC-1295 (no DAC) paired with Ipamorelin is widely considered the "gold standard" GH secretagogue stack, while MK-677 adds oral convenience and sustained GH elevation through a complementary ghrelin-mimetic mechanism.

Stack Overview

Alternative GHRPs

• GHRP-6 — Stronger GH release than Ipamorelin but causes significant appetite stimulation and cortisol/prolactin elevation
• GHRP-2 — Potent GH release with moderate appetite stimulation, sits between Ipamorelin and GHRP-6 in side effect profile

The GHRH + GHRP Synergy Mechanism

The pituitary somatotroph cell has two distinct receptor systems for GH release:

1. GHRH receptor (GHRH-R) — When activated by GHRH or its analogs (CJC-1295, Sermorelin), it increases the amplitude of each GH pulse via the cAMP/PKA signaling pathway
2. Growth Hormone Secretagogue Receptor (GHS-R1a) — When activated by ghrelin or ghrelin mimetics (Ipamorelin, GHRP-2, GHRP-6), it increases the frequency of GH pulses via the IP3/DAG/PKC pathway

When both receptors are activated simultaneously, the resulting GH output is synergistic rather than merely additive. A landmark study by Bowers et al. demonstrated that combined GHRH + GHRP administration produced GH levels approximately 2-3x greater than the sum of either alone Bowers et al., 1990.

The key insight: GHRH says "release more GH per pulse" while GHRP says "pulse more often." Together, they produce bigger pulses, more frequently — a multiplicative rather than additive effect on total GH output.

This synergy also involves suppression of somatostatin. GHRPs attenuate somatostatin's inhibitory tone on the pituitary, further amplifying the GHRH signal Hataya et al., 2001.

Individual Peptide Roles

CJC-1295 (no DAC): The Pulse Amplifier

CJC-1295 without DAC (also known as Mod GRF 1-29) is a modified 29-amino acid fragment of GHRH with four amino acid substitutions that resist enzymatic degradation, extending its half-life from approximately 7 minutes (native GHRH) to approximately 30 minutes.

• Mechanism — Binds the GHRH receptor and activates adenylyl cyclase, increasing intracellular cAMP and triggering GH release from stored vesicles Teichman et al., 2006
• Selectivity — Specifically stimulates GH release without significant effects on other pituitary hormones (ACTH, TSH, prolactin, LH, FSH)
• Pulsatile pattern — Preserves the natural pulsatile pattern of GH secretion, unlike exogenous GH injection which creates a flat, supraphysiological profile
• Feedback preservation — Because it works through the natural GHRH receptor, negative feedback mechanisms remain intact, reducing the risk of GH excess

DAC vs No-DAC Considerations

Most research protocols favor the no-DAC variant for its more physiological GH release pattern and superior synergy timing with GHRPs.

Ipamorelin: The Clean GHRP

Ipamorelin is a pentapeptide GH secretagogue that selectively activates the ghrelin receptor (GHS-R1a). It is considered the "cleanest" GHRP because of its highly selective GH release profile.

• Selective GH release — Unlike GHRP-6 and GHRP-2, Ipamorelin does not significantly increase cortisol, prolactin, or ACTH at standard doses Raun et al., 1998
• No appetite stimulation — Does not activate the hypothalamic appetite centers the way GHRP-6 does, making it suitable for protocols where appetite control matters
• Dose-dependent — GH release scales linearly with dose up to a saturation point of approximately 1 mcg/kg Gobburu et al., 1999
• Sleep enhancement — Promotes deeper slow-wave sleep when dosed before bed, aligning with the body's natural nocturnal GH surge Frieboes et al., 1999

MK-677 (Ibutamoren): The Oral Sustainer

MK-677 is not technically a peptide but a non-peptide spiropiperidine that mimics ghrelin's action at the GHS-R1a receptor. Its primary advantage is oral bioavailability and a long half-life (~24 hours), providing sustained GH elevation.

• Oral administration — Eliminates the need for injection, improving convenience and compliance
• 24-hour IGF-1 elevation — A single daily dose maintains elevated IGF-1 levels throughout the day Chapman et al., 1996
• Long-term efficacy — Studies of up to 2 years show sustained IGF-1 elevation without significant tachyphylaxis Nass et al., 2008
• Sleep architecture — Increases duration of stage IV (deep) sleep by approximately 50% and REM sleep by approximately 20% Copinschi et al., 1997
• Appetite stimulation — MK-677 does increase appetite, particularly in the first few weeks of use. This can be beneficial for bulking protocols but counterproductive for fat loss

Research Protocol

Primary Protocol: CJC-1295 (no DAC) + Ipamorelin

Adding MK-677

Full Stack Protocol Table

Timing Considerations

• Fasting — GH release is blunted by elevated blood glucose and insulin. Inject at least 2 hours after eating. Fasting states produce the strongest GH response
• Post-exercise — GH release is naturally elevated post-training. Injecting 15-30 minutes after exercise can amplify this effect, though the evidence is mixed
• Before sleep — The largest natural GH pulse occurs during the first 90 minutes of sleep. Pre-bed dosing amplifies this pulse, synergizing with endogenous GHRH release
• Avoid dosing with food — This applies to both injectable peptides and MK-677. A minimum 2-hour fast before and 30 minutes after dosing is standard protocol

Cycling Recommendations

• Receptor desensitization — GHS-R1a can desensitize with prolonged continuous GHRP use. Cycling mitigates this risk. Some protocols use 5 days on / 2 days off within a cycle
• MK-677 long-term use — The Nass et al. 2008 study demonstrated efficacy over 2 years, but glucose monitoring is essential for extended use
• GHRP rotation — Some protocols alternate between Ipamorelin, GHRP-2, and GHRP-6 to reduce receptor adaptation

Blood Work & Monitoring

Baseline (Before Starting)

Mid-Protocol (Week 4-6)

• IGF-1 — Expect 30-100% elevation from baseline depending on dose and individual response
• Fasting glucose — MK-677 can raise fasting glucose by 5-15 mg/dL. Values approaching 100 mg/dL warrant dose reduction or discontinuation
• HbA1c — Recheck if fasting glucose is elevated
• Repeat CMP — Ensure liver and kidney function remain stable

Post-Protocol (4 Weeks After Cessation)

• Full panel repeat to confirm return to baseline
• IGF-1 should normalize within 2-4 weeks of discontinuation

Safety Considerations

• MK-677 and glucose — The most significant safety concern in this stack. MK-677 can cause insulin resistance and elevate fasting glucose, particularly at higher doses (25 mg) and with prolonged use. Individuals with pre-diabetes, metabolic syndrome, or family history of diabetes should use with extreme caution or avoid MK-677 entirely Svensson et al., 1998
• Water retention and bloating — GH elevation increases sodium and water retention. Expect 2-5 lbs of water weight in the first 1-2 weeks. This typically stabilizes but can exacerbate existing edema or hypertension
• Carpal tunnel symptoms — Tingling and numbness in hands and fingers can occur with elevated GH/IGF-1. This is dose-dependent and typically resolves with dose reduction
• Joint pain — Some individuals experience joint stiffness with elevated GH. This is usually transient
• MK-677 appetite — Can be significant, especially in the first 2-4 weeks. This is a ghrelin-mediated effect and may not be desirable in fat loss protocols
• Prolactin and cortisol — Not a concern with Ipamorelin, but relevant if substituting GHRP-2 or GHRP-6. Monitor prolactin if using these alternatives
• Cancer risk — Elevated IGF-1 is epidemiologically associated with increased risk of certain cancers (prostate, breast, colorectal). While causation is not established, individuals with active malignancies or strong family history should exercise caution Renehan et al., 2004

Important: Do not combine this stack with exogenous GH (somatropin). The mechanisms are complementary in theory but the risk of excessive IGF-1 elevation and associated side effects is significant. Choose one approach or the other.

References

1. Bowers et al., 1990 — Synergistic release of growth hormone by GHRP and GHRH
2. Hataya et al., 2001 — A low dose of ghrelin stimulates growth hormone release synergistically with GHRH in humans
3. Teichman et al., 2006 — Prolonged stimulation of growth hormone and IGF-1 secretion by CJC-1295
4. Raun et al., 1998 — Ipamorelin, the first selective growth hormone secretagogue
5. Gobburu et al., 1999 — Pharmacokinetic-pharmacodynamic modeling of ipamorelin
6. Frieboes et al., 1999 — Growth hormone-releasing peptide-6 stimulates sleep, GH, ACTH, and cortisol release in normal man
7. Chapman et al., 1996 — Stimulation of the growth hormone-IGF-1 axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects
8. Nass et al., 2008 — Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults
9. Copinschi et al., 1997 — Effects of a 7-day treatment with a novel, orally active, growth hormone secretagogue MK-677 on 24-hour GH profiles
10. Svensson et al., 1998 — Two-month treatment with the oral GH secretagogue MK-677: effects on glucose tolerance
11. Renehan et al., 2004 — IGF-I and cancer: a meta-analysis